As of January, 2021, nearly 2-million deaths worldwide have been attributed to COVID-19,
which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Much …

Since the very first cases of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
infection were identified in China, patients with severe manifestations of COVID-19 have …

Hoffmann-La Roche has announced disappointing results from its much-anticipated phase 3
COVACTA trial of tocilizumab, raising questions about the efficacy of interleukin (IL)-6 …

Individuals with inflammatory rheumatic disease require special consideration with regard to
coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome …

Comment e676 www. thelancet. com/rheumatology Vol 3 October 2021 8375 [90· 1%]
women and 893 [9· 6%] men) between April 3 and May 8, 2020. The most frequent …

In a subgroup of patients, severe acute respiratory syndrome corona virus 2 (SARSCoV2)
induces a hyper inflammatory response that leads to acute respiratory dis tress syndrome. 1 …

As of mid-April, 2020, severe acute respiratory syn drome coronavirus 2 (SARS-CoV-2), the
coronavirus respon sible for COVID-19, has infected more than 4· 4 million people …

Early in the COVID-19 pandemic, there was concern in the media that the use of non-
steroidal antiinflammatory drugs (NSAIDs), particularly ibuprofen, might exacerbate COVID …

Although viruses can induce rheumatic diseases, the impact of SARS-CoV-2, the virus
behind COVID-19, on the development of systemic rheumatic disease is unclear. COVID-19 …

There is a continuous debate about the risks of increased incidence of COVID-19 in
vulnerable patient groups, which includes patients with rheumatic diseases and especially …